Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Total Liabilities (2019 - 2025)

Allogene Therapeutics' Total Liabilities history spans 7 years, with the latest figure at $124.4 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 0.74% year-over-year to $124.4 million; the TTM value through Sep 2025 reached $124.4 million, down 0.74%, while the annual FY2024 figure was $126.5 million, 3.12% down from the prior year.
  • Total Liabilities for Q3 2025 was $124.4 million at Allogene Therapeutics, down from $126.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $154.6 million in Q1 2023 and bottomed at $99.4 million in Q1 2022.
  • The 5-year median for Total Liabilities is $126.0 million (2025), against an average of $128.6 million.
  • The largest annual shift saw Total Liabilities skyrocketed 55.6% in 2023 before it dropped 19.16% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $122.2 million in 2021, then increased by 23.71% to $151.2 million in 2022, then dropped by 13.63% to $130.6 million in 2023, then fell by 3.12% to $126.5 million in 2024, then decreased by 1.65% to $124.4 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Total Liabilities are $124.4 million (Q3 2025), $126.0 million (Q2 2025), and $122.6 million (Q1 2025).